Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Gain Therapeutics Inc GANX

Healthcare Biotechnology
Gain Therapeutics, Inc. is a biotechnology company. The Company is focused on developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company’s drug... see more

Recent & Breaking News (NDAQ:GANX)

Gain Therapeutics Announces Proposed Public Offering

GlobeNewswire June 13, 2024

Gain Therapeutics Announces Acceptance of Late-Breaking Abstract for Poster Presentation at Federation of European Neuroscience Societies (FENS) Forum 2024

GlobeNewswire May 30, 2024

Gain Therapeutics Reports Financial Results for First Quarter 2024 and Provides Corporate Update

GlobeNewswire May 14, 2024

Gain Therapeutics Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for GBA1 Parkinson's Disease

GlobeNewswire April 24, 2024

Gain Therapeutics Bolsters Management Team with the Appointment of Gene Mack as Chief Financial Officer

GlobeNewswire April 8, 2024

Gain Therapeutics Strengthens Management Team and Appoints Jonas Hannestad, M.D., Ph.D. as Chief Medical Officer

GlobeNewswire April 1, 2024

Gain Therapeutics Reports Financial Results for Year End 2023 and Provides Corporate Update

GlobeNewswire March 26, 2024

Gain Therapeutics to Present at Public Ventures Discovery Day

GlobeNewswire March 15, 2024

Gain Therapeutics Presents Data at the AD/PD(TM) 2024 Conference Demonstrating the Mechanism of Action of GT-02287, its Clinical Stage GCase Regulator for the Treatment of Parkinson's Disease

GlobeNewswire March 5, 2024

Gain Therapeutics Announces the Initiation of the Multiple Ascending Dose (MAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson's Disease

GlobeNewswire February 27, 2024

Gain Therapeutics Announces 2024 R&D Update on Parkinson's Disease with KOL & Analyst Insight

GlobeNewswire February 14, 2024

UPDATE - Gain Therapeutics' GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson's Disease

GlobeNewswire February 6, 2024

Gain Therapeutics' GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson's Disease

GlobeNewswire February 6, 2024

Gain Therapeutics' CEO Matthias Alder Issues Letter to Shareholders and Provides Operational Update

GlobeNewswire January 31, 2024

Gain Therapeutics Announces Acceptance of Late-Breaking Abstract for Platform Presentation at the 20th Annual WORLDSymposium(TM) 2024

GlobeNewswire January 2, 2024

Gain Therapeutics to Participate in FORCE Family Office Event with Zacks Small-Cap Research

GlobeNewswire December 4, 2023

Gain Therapeutics Announces Preclinical Data Showing Restoration of Enzymatic Function with Novel Allosteric Regulators in GM1 Gangliosidosis Model

GlobeNewswire December 1, 2023

Gain Therapeutics to Participate in AI Driven Drug Discovery Summit

GlobeNewswire November 29, 2023

Gain Therapeutics Announces Closing of $10.1 Million Public Offering and Concurrent Private Placement of Common Stock and Warrants, Including Full Exercise of Over-Allotment Option

GlobeNewswire November 24, 2023

Gain Therapeutics Announces Pricing of $9.4 Million Public Offering and Concurrent Private Placement of Common Stock and Warrants

GlobeNewswire November 21, 2023